No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study
ObjectiveTo study the efficacy of interval debulking surgery (IDS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) compared to IDS alone for the treatment of ovarian cancer after neoadjuvant chemotherapy (NACT).MethodsWe conducted a retrospective study of patients with stage IIIC/IV high-grad...
Main Authors: | Mengmeng Lyu, Jin Lu, Yang Shen, Qianqian Chen, Fei Deng, Jinhua Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Surgery |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fsurg.2022.997344/full |
Similar Items
-
Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: Single-institution cohort study
by: Yong Jae Lee, et al.
Published: (2022-07-01) -
HIPEC after Interval Debulking Surgery as Best Clinical Practice in Ovarian Cancer Patients: Case Series and Literature Review
by: Stefano Restaino, et al.
Published: (2022-06-01) -
Hyperthermic Intraperitoneal Chemotherapy (HIPEC): New Approaches and Controversies on the Treatment of Advanced Epithelial Ovarian Cancer—Systematic Review and Meta-Analysis
by: Luigi Della Corte, et al.
Published: (2023-11-01) -
Combined Interval Cytoreductive Surgery and Carboplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Advanced Primary High-Grade Serous Ovarian Cancer
by: Claudèle Brault, et al.
Published: (2023-12-01) -
The Feasibility of Cardiophrenic Lymphnode Assessment and Removal in Patients Requiring Diaphragmatic Resection During Interval Debulking Surgery for Ovarian Cancer
by: Ciro Pinelli, et al.
Published: (2021-08-01)